NAGE
Niagen Bioscience, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.56
+8.26%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.41
From 52W high−64.42%
Volume366453.00
Market cap$202.17M
P/E (TTM)13.2x
P/S (TTM)1.6x
Div yield—
Key dataNov 4, 2026
Open
$2.41
From 52W high
−64.42%
Volume
366453.00
Market cap
$202.17M
ValuationView details →
P/E (Fwd)
32.4x
EV/EBITDA
7.5x
P/E (TTM)
13.2x
RSI (14)
48.2
MomentumView details →
1D Return
+8.26%
YTD Return
−59.75%
SummaryUpdated Jun 1, 2026
ChromaDex Corporation (NASDAQ:CDXC) is a bioscience company founded in 1999 and headquartered in Los Angeles, California. The company specializes in healthy aging research and is a leader in the development of nicotinamide adenine dinucleotide (NAD) precursor technologies. ChromaDex went public in 2015 and has evolved from a contract research organization into a consumer health company focused on NAD boosting supplements and potential pharmaceutical applications. The company is known for its proprietary ingredient Niagen and its consumer brand TRU NIAGEN, which targets the growing market of consumers interested in longevity and cellular health optimization.
Similar companies
Latest newsMore news →
Niagen Bioscience launched its prescription-only, clinician-directed Niagen At-Home Injection Kit, featuring the company's first ready-to-inject liquid formulation with nicotinamide riboside.13d agoNiagen Bioscience announced the debut of Tru Niagen Skincare as a permanent category in its core Tru Niagen line, led by Niagen NanoCloud, its first dermatologist-tested topical product powered by Niagen.15d ago